The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.e

Bradycardia

Publications

Qiu Y, Li B, Zhang Y, Guo X, Xiang C, Wang C, Lu Y, Ren S, Zhao J

ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.

Medicine. 2019;98(11):e14826

Kwan Lung K, Liu C, Cheung B

Severe bradycardia associated with crizotinib.

Postgraduate medical journal. 2017;93(1106):774-775

Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Lung cancer (Amsterdam, Netherlands). 2015;87(2):89-95

Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Expert review of anticancer therapy. 2015;15(2):225-33

Ou SH, Azada M, Dy J, Stiber JA

Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(12):2135-7